The Food and Drug Administration said on Friday it received seven reports concerning individuals who have become sick due to compounded steroid injections distributed by Tennessee-based Main Street Family Pharmacy LLC, according to Reuters.

According to the FDA, as of right now the investigation is still in process. However, the agency says some of the illness seemed to come from infections and “at least of those infections appears to be fungal in nature.”

The illnesses have been linked to the New England Compounding Center, based in Framingham, Massachusetts. The tainted steroid, methylprednisolone acetate, was also linked to an outbreak of meningitis in 2012 that killed 53 people and made 700 ill.

According to a statement from the Tennessee Department of Health, the reports came after December 6, from individuals in Illinois and North Carolina who had gotten injections of type of methylprednisolone acetate that had no preservatives.

"An investigation into the exact source of these adverse events is still ongoing," said the FDA, "but these cases are associated with a potentially contaminated medication."

Usually, the drug is taken to help relieve back pain. Currently, the number of patients who took the steroid is unknown.

According to the Tennessee health department, the drugs were released to 13 states—Florida, Illinois, Mississippi, New Mexico, South Carolina, Tennessee, Texas, Arkansas, Kentucky, North Carolina California, Louisiana, and Alabama.

"Health departments and facilities in these states are being notified so they can participate in response efforts," the statement says."It is too early to know how many additional patients, if any, may be at risk.”

"The first priority is to ensure all products from this pharmacy are no longer in use," the department added.

Currently the state is looking at the pharmacy’s records to determine at what time and to what locations the drugs were shipped. It is also looking into the causes of the reported illnesses.

These reports come at a time when Congress is considering handing the FDA more authority over certain practices by compounding pharmacies.